Astellas Announces Opening of Phase 1b Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ASP0367

September 1, 2022

On Sept. 1, 2022, Astellas announced that their Phase 1b study is now open at sites across the United States. They will be adding more sites as they become ready to accept new participants. 

The primary purpose of the study is to evaluate the safety and tolerability, and to evaluate how the body processes ASP0367 and how it affects muscle function.

Please download and read their Community Newsletter below.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open